Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer.

MLA

Chun, Brie, et al. “Changes in T-Cell Subsets and Clonal Repertoire during Chemoimmunotherapy with Pembrolizumab and Paclitaxel or Capecitabine for Metastatic Triple-Negative Breast Cancer.” Journal for Immunotherapy of Cancer, vol. 10, no. 1, Jan. 2022. EBSCOhost, https://doi.org/10.1136/jitc-2021-004033.

APA

Chun, B., Pucilowska, J., Chang, S., Kim, I., Nikitin, B., Koguchi, Y., Redmond, W. L., Bernard, B., Rajamanickam, V., Polaske, N., Fields, P. A., Conrad, V., Schmidt, M., Urba, W. J., Conlin, A. K., McArthur, H. L., & Page, D. B. (2022). Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer. Journal for Immunotherapy of Cancer, 10(1). https://doi.org/10.1136/jitc-2021-004033

Chicago

Chun, Brie, Joanna Pucilowska, ShuChing Chang, Isaac Kim, Benjamin Nikitin, Yoshinobu Koguchi, William L Redmond, et al. 2022. “Changes in T-Cell Subsets and Clonal Repertoire during Chemoimmunotherapy with Pembrolizumab and Paclitaxel or Capecitabine for Metastatic Triple-Negative Breast Cancer.” Journal for Immunotherapy of Cancer 10 (1). doi:10.1136/jitc-2021-004033.